Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-concept
Speicher T, Burgard C, Rosar F, Bastian M, Bartholomä M, Maus S, Ezziddin S (2026)
Publication Type: Journal article
Publication year: 2026
Journal
Book Volume: 51
Pages Range: e25-e26
Journal Issue: 1
DOI: 10.1097/RLU.0000000000005936
Abstract
We present a case of a 69-year-old woman with metastasized small bowel NET G2 initially treated with somatostatin analogs (SSA). Disease progression was observed under SSA, and poor tracer uptake on [68Ga]Ga-DOTATOC PET/CT precluded peptide receptor radionuclide therapy (PRRT). Subsequently, evaluation with [68Ga]Ga-NODAGA-LM3 PET/CT was performed, which showed markedly better and treatment-sufficient uptake, enabling initiation of PRRT with [177Lu]Lu-DOTA-LM3. After 4 therapy cycles, a positive response was observed. This interesting case nicely demonstrates not only the diagnostic superiority of somatostatin receptor antagonist (over agonist) imaging but also the direct translation into successful targeted peptide-mediated radionuclide therapy.
Involved external institutions
Germany (DE)How to cite
APA:
Speicher, T., Burgard, C., Rosar, F., Bastian, M., Bartholomä, M., Maus, S., & Ezziddin, S. (2026). Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-concept. Clinical Nuclear Medicine, 51(1), e25-e26. https://doi.org/10.1097/RLU.0000000000005936
MLA:
Speicher, Tilman, et al. "Superior NET Targeting by Switch From Agonist to Antagonist-mediated Somatostatin Receptor Theranostics Allowing Successful (LM3-based) PRRT of Otherwise Precluded mNET: Intraindividual Proof-of-concept." Clinical Nuclear Medicine 51.1 (2026): e25-e26.
BibTeX: Download